WO2001041754A3 - Inhibiteurs d'agregation plaquettaire induite par le collagene - Google Patents

Inhibiteurs d'agregation plaquettaire induite par le collagene Download PDF

Info

Publication number
WO2001041754A3
WO2001041754A3 PCT/US2000/042370 US0042370W WO0141754A3 WO 2001041754 A3 WO2001041754 A3 WO 2001041754A3 US 0042370 W US0042370 W US 0042370W WO 0141754 A3 WO0141754 A3 WO 0141754A3
Authority
WO
WIPO (PCT)
Prior art keywords
platelet aggregation
collagen
inhibitors
induced platelet
condition
Prior art date
Application number
PCT/US2000/042370
Other languages
English (en)
Other versions
WO2001041754A2 (fr
WO2001041754A8 (fr
WO2001041754A9 (fr
Inventor
Fatih M Uckun
Original Assignee
Parker Hughes Inst
Fatih M Uckun
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Parker Hughes Inst, Fatih M Uckun filed Critical Parker Hughes Inst
Priority to CA002390857A priority Critical patent/CA2390857A1/fr
Priority to AU45086/01A priority patent/AU4508601A/en
Priority to JP2001543099A priority patent/JP2003516351A/ja
Priority to EP00992536A priority patent/EP1235567A2/fr
Publication of WO2001041754A2 publication Critical patent/WO2001041754A2/fr
Priority to US10/077,514 priority patent/US6589992B2/en
Publication of WO2001041754A3 publication Critical patent/WO2001041754A3/fr
Publication of WO2001041754A9 publication Critical patent/WO2001041754A9/fr
Publication of WO2001041754A8 publication Critical patent/WO2001041754A8/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne une méthode thérapeutique utilisée pour traiter ou prévenir un état pathologique d'agrégation plaquettaire chez un sujet. Cette méthode consiste à administrer une quantité pharmaceutiquement efficace d'un composé ou d'une composition inhibant l'agrégation plaquettaire induite par la tyrosine kinase de Bruton et par le collagène. L'état pathologique d'agrégation plaquettaire englobe les maladies cardio-vasculaires, hématopoïétiques et les maladies vasculaires cérébrales.
PCT/US2000/042370 1999-11-30 2000-11-29 Inhibiteurs d'agregation plaquettaire induite par le collagene WO2001041754A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA002390857A CA2390857A1 (fr) 1999-11-30 2000-11-29 Inhibiteurs d'agregation plaquettaire induite par le collagene
AU45086/01A AU4508601A (en) 1999-11-30 2000-11-29 Inhibitors of collagen-induced platelet aggregation
JP2001543099A JP2003516351A (ja) 1999-11-30 2000-11-29 コラーゲン誘導血小板凝集阻害剤
EP00992536A EP1235567A2 (fr) 1999-11-30 2000-11-29 Inhibiteurs d'agregation plaquettaire induite par le collagene
US10/077,514 US6589992B2 (en) 1999-11-30 2002-02-15 Inhibiting collagen-induced platelet aggregation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16810399P 1999-11-30 1999-11-30
US60/168,103 1999-11-30

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/077,514 Continuation US6589992B2 (en) 1999-11-30 2002-02-15 Inhibiting collagen-induced platelet aggregation

Publications (4)

Publication Number Publication Date
WO2001041754A2 WO2001041754A2 (fr) 2001-06-14
WO2001041754A3 true WO2001041754A3 (fr) 2002-03-21
WO2001041754A9 WO2001041754A9 (fr) 2002-08-01
WO2001041754A8 WO2001041754A8 (fr) 2003-10-23

Family

ID=22610139

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/042370 WO2001041754A2 (fr) 1999-11-30 2000-11-29 Inhibiteurs d'agregation plaquettaire induite par le collagene

Country Status (5)

Country Link
EP (1) EP1235567A2 (fr)
JP (1) JP2003516351A (fr)
AU (1) AU4508601A (fr)
CA (1) CA2390857A1 (fr)
WO (1) WO2001041754A2 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7691839B2 (en) 2005-09-28 2010-04-06 Biovascular, Inc. Methods and compositions for blocking platelet and cell adhesion, cell migration and inflammation
US9133198B2 (en) 2006-09-22 2015-09-15 Pharmacyclics Llc Inhibitors of bruton'S tyrosine kinase

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1981888A4 (fr) 2006-01-13 2010-10-13 Pharmacyclics Inc Inhibiteurs de tyrosine kinase et leurs utilisations
US8809273B2 (en) 2007-03-28 2014-08-19 Pharmacyclics, Inc. Inhibitors of Bruton's tyrosine kinase
WO2010009342A2 (fr) 2008-07-16 2010-01-21 Pharmacyclics, Inc. Inhibiteurs de tyrosine kinase de bruton pour le traitement de tumeurs solides
CN103153311A (zh) 2010-06-03 2013-06-12 药品循环公司 布鲁顿酪氨酸激酶(btk)抑制剂的应用
EA201490265A1 (ru) 2011-07-13 2014-12-30 Фармасайкликс, Инк. Ингибиторы тирозинкиназы брутона
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
BR112014030424A8 (pt) 2012-06-04 2017-07-11 Pharmacyclics Inc Formas cristalinas de um inibidor de quinase de tirosina de bruton
EP2877598A1 (fr) 2012-07-24 2015-06-03 Pharmacyclics, Inc. Mutations associées à la résistance à des inhibiteurs de la tyrosine kinase de bruton (btk)
MX2015006168A (es) 2012-11-15 2015-08-10 Pharmacyclics Inc Compuestos de pirrolopirimidina como inhibidores de quinasas.
TWI649081B (zh) 2013-08-02 2019-02-01 製藥公司 治療固態腫瘤之方法
EP3033079B1 (fr) 2013-08-12 2018-10-31 Pharmacyclics LLC Méthodes de traitement d'un cancer amplifié par her2
BR112016006978A2 (pt) 2013-09-30 2017-08-01 Pharmacyclics Llc inibidores de tirosina quinase de bruton
CA3103411A1 (fr) 2013-10-25 2015-04-30 Pharmacyclics Llc Utilisation de l'ibrutinib pour le traitement et la prevention de la maladie chronique du greffon contre l'hote
CA2942528A1 (fr) 2014-03-20 2015-09-24 Pharmacyclics Inc. Mutations de phospholipase c gamma 2 et associees aux resistances
CN106999494A (zh) 2014-08-01 2017-08-01 药品循环有限公司 布鲁顿酪氨酸激酶的抑制剂
BR112017002231A2 (pt) 2014-08-07 2018-07-17 Pharmacyclics Llc novas formulações de um inibidor de tirosina cinase de bruton
SI3265084T1 (sl) 2015-03-03 2024-04-30 Pharmacyclics Llc Farmacevtske formulacije inhibitorja Burtonove tirozin kinaze

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0607775A2 (fr) * 1993-01-08 1994-07-27 Hoechst Aktiengesellschaft Utilisation de leflunomid pour inhiber interleukin 1 bêta
EP0652214A1 (fr) * 1993-11-04 1995-05-10 Roussel Uclaf Nouveaux dérivés N-aryl 2-cyano 3-hydroxy propénamides, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant
EP0821952A1 (fr) * 1996-07-31 1998-02-04 Hoechst Aktiengesellschaft L'usage des dérivés d'isoxazole et d'amide d'acide crotonique pour la modulation de l'apoptose
WO1999054286A2 (fr) * 1998-04-17 1999-10-28 Parker Hughes Institute Inhibiteurs btk et leurs procedes d'identification et d'utilisation
WO2000056737A2 (fr) * 1999-03-19 2000-09-28 Parker Hughes Institute Calanolides inhibitrices du btk

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0607775A2 (fr) * 1993-01-08 1994-07-27 Hoechst Aktiengesellschaft Utilisation de leflunomid pour inhiber interleukin 1 bêta
EP0652214A1 (fr) * 1993-11-04 1995-05-10 Roussel Uclaf Nouveaux dérivés N-aryl 2-cyano 3-hydroxy propénamides, leur procédé de préparation, leur application comme médicaments et les compositions pharmaceutiques les renfermant
EP0821952A1 (fr) * 1996-07-31 1998-02-04 Hoechst Aktiengesellschaft L'usage des dérivés d'isoxazole et d'amide d'acide crotonique pour la modulation de l'apoptose
WO1999054286A2 (fr) * 1998-04-17 1999-10-28 Parker Hughes Institute Inhibiteurs btk et leurs procedes d'identification et d'utilisation
WO2000056737A2 (fr) * 1999-03-19 2000-09-28 Parker Hughes Institute Calanolides inhibitrices du btk

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
MAHAJAN S ET AL: "RATIONAL DESIGN AND SYNTHESIS OF A NOVEL ANTI-LEUKEMIC AGENT TARGETING BRUTON'S TYROSINE KINASE (BTK), LFM-A13 UALPHA-CYANO-BETA-HYDROXY-BET A-METHYL-N-(2,5-DIBROMOPHENYL)PROPENAMIDE", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 274, no. 14, 2 April 1999 (1999-04-02), pages 9587 - 9599, XP000856755, ISSN: 0021-9258 *
TIBBLES H E ET AL: "Inhibition of collagen-induced platelet aggregation by selectively targeting Bruton's tyrosine kinase with LFM-A13.", BLOOD, vol. 94, no. 10 SUPPL. 1 PART 1, 15 November 1999 (1999-11-15), Forty-first Annual Meeting of the American Society of Hematology;New Orleans, Louisiana, USA; December 3-7, 1999, pages 221a, XP001024606, ISSN: 0006-4971 *
TIBBLES HEATHER E ET AL: "Prevention of fatal thromboembolism in mice by selectively targeting BTK and TEC kinases in platelets with alpha-cyano-beta-hydroxy-beta-m ethyl-N-(2,5-dibromophenyl)-propenamide (LFM-A13).", BLOOD, vol. 96, no. 11 Part 1, 16 November 2000 (2000-11-16), 42nd Annual Meeting of the American Society of Hematology;San Francisco, California, USA; December 01-05, 2000, pages 275a, XP001024610, ISSN: 0006-4971 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7691839B2 (en) 2005-09-28 2010-04-06 Biovascular, Inc. Methods and compositions for blocking platelet and cell adhesion, cell migration and inflammation
US8188034B2 (en) 2005-09-28 2012-05-29 Biovascular, Inc. Methods and compositions for blocking platelet and cell adhesion, cell migration and inflammation
US9133198B2 (en) 2006-09-22 2015-09-15 Pharmacyclics Llc Inhibitors of bruton'S tyrosine kinase
US9181257B2 (en) 2006-09-22 2015-11-10 Pharmacyclics Llc Inhibitors of Bruton's tyrosine kinase

Also Published As

Publication number Publication date
WO2001041754A2 (fr) 2001-06-14
AU4508601A (en) 2001-06-18
CA2390857A1 (fr) 2001-06-14
EP1235567A2 (fr) 2002-09-04
JP2003516351A (ja) 2003-05-13
WO2001041754A8 (fr) 2003-10-23
WO2001041754A9 (fr) 2002-08-01

Similar Documents

Publication Publication Date Title
WO2001041754A3 (fr) Inhibiteurs d'agregation plaquettaire induite par le collagene
WO2001045641A3 (fr) Inhibiteurs d'agregation de plaquettes induite par thrombine
BR0013704A (pt) Uso de inibidores do sistema renina-angiotensina na prevenção de casos cardiovasculares
SI1509232T1 (sl) Kombinacija antagonista nmda in zaviralcev acetilholinesteraze za zdravljenje alzheimerjeve bolezni
MXPA03004358A (es) Combinaciones sinergicas que comprenden un inhibidor de renina para enfermedades cardiovasculares.
BR9814923A (pt) Método para tratamento de doença de alzheimer
YU63699A (sh) Preparati za tretiranje i prevenciju arterijske tromboze i korišćenje inhibitora faktora xa samog ili u kombinaciji sa plateletnim antiagregacionim agensom
WO2003092606A3 (fr) Inhibiteurs de cholinesterase pour prevenir les blessures causees par des produits chimiques
WO2003015690A3 (fr) Methode de traitement de l'insomnie primaire
WO2006015970A3 (fr) Medicaments pour la prevention ou le traitement de la pneumonie alveolaire comprenant un anticholinergique
WO2003059254A3 (fr) Prevention et traitement de l'atherosclerose et de la restenose
EP0799618A3 (fr) Utilisation d'antagonistes de l'adrénorécepteur alpha 1 dans la fabrication d'unmédicament pur la prévention et au traitment du cancer
WO2002022112A3 (fr) Composition pharmaceutique pour prevenir ou traiter une maladie associee a une production excessive d'il-12
WO2001000189A3 (fr) Combinaison d'inhibiteurs de mtp et principes actifs agissant sur le metabolisme et leur utilisation dans les medicaments
EP1584333A3 (fr) Utilisation d'inhibiteurs de l'acétylcoenzime A pour traiter l'Alzheimer
WO2001074341A3 (fr) Compositions et procedes pour le traitement d'etats allergiques et inflammatoires avec toux
EP1714676A3 (fr) Utilisation de composés 1,5-didesoxy-1,5-imino-D-glucitol N-substitutés pour traiter des infections par un virus de l'hépatite
EP1194162A4 (fr) Compositions et procedes de prevention, de traitement et de detection de la tuberculose et d'autres maladies
WO2003093415A3 (fr) Methodes utilisees dans le traitement et la prevention d'une infection par vih
HK1058305A1 (en) Combinations of dalfopristine/quinupristine with cefpirome
GB9929597D0 (en) New and improved composition and method for the treatment of drug abuse
GB9929595D0 (en) New composition and method for the treatment of drug abuse
GB9922405D0 (en) New composition and method for the treatment of drug abuse
WO2002076405A3 (fr) Compositions et methodes de traitement de maladies ulceratives, de brulures, et d'etats associes
GB9930342D0 (en) Improved composition and method for the treatment of drug abuse

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ CZ DE DE DK DK DM DZ EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 10077514

Country of ref document: US

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ CZ DE DE DK DK DM DZ EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 45086/01

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2390857

Country of ref document: CA

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 543099

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000992536

Country of ref document: EP

AK Designated states

Kind code of ref document: C2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1/2-2/2, DRAWINGS, REPLACED BY NEW PAGES 1/2-2/2; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

WWP Wipo information: published in national office

Ref document number: 2000992536

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2000992536

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

CFP Corrected version of a pamphlet front page
CR1 Correction of entry in section i

Free format text: IN PCT GAZETTE 24/2001 DUE TO A TECHNICAL PROBLEM AT THE TIME OF INTERNATIONAL PUBLICATION, SOME INFORMATION WAS MISSING (81). THE MISSING INFORMATION NOW APPEARS IN THE CORRECTED VERSION.